GW 405833

Key Product Details

Product Description

Potent and selective CB₂ receptor partial agonist (EC₅₀ = 0.65 nM; maximum inhibition = 44.6%). Binds with high affinity to both human and rat CB₂ receptors and displays ~ 1200-fold selectivity over CB₁ (K_i values are 3.92 and 4772 nM for human recombinant CB₂ and CB₁ receptors respectively). Produces potent antihyperalgesic effects in several rodent models of pain.

Product Specifications for GW 405833

The technical data provided above is for guidance only. For batch specific data refer to the Certificate of Analysis.

Solubility

Preparing Stock Solutions for GW 405833

The following data is based on the product molecular weight 447.36.

Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which all affect the solvent volumes required to prepare stock solutions.

Select a batch to recalculate based on the batch molecular weight:

3 2 1 Recalculate

Concentration / Solvent Volume / Mass	1 mg	5 mg	10 mg
0.5 mM	4.47 mL	22.35 mL	44.71 mL
2.5 mM	0.89 mL	4.47 mL	8.94 mL
5 mM	0.45 mL	2.24 mL	4.47 mL
25 mM	0.09 mL	0.45 mL	0.89 mL

Calculators

Background References

References are publications that support the biological activity of the product. See our Citations tab to view 7 publications citing the usage of this product.

• Valenzano Pharmacological and pharmacokinetic characterization of the cannabinoid receptor 2 agonist, GW405833, utilizing rodent models of acute and chronic pain, anxiety, ataxia and catalepsy. Neuropharmacology 2005 PMID: 15814101
• Clayton CB₁ and CB₂ cannabinoid receptors are implicated in inflammatory pain. Pain 2002 PMID: 11972997

Product Documents for GW 405833